The intended audience for this activity includes a wide range of health care professionals; many may deem this presentation beneficial.

Upon completion of this activity, learners should be able to:

1. Describe the principles of gender affirming hormone replacement therapy (HRT)
2. Explain the risks and benefits of HRT to patients and other medical providers
3. Apply informed consent and risk reduction models to patient care
4. Be prepared to appropriately initiate and monitor gender affirming hormone replacement therapy in uncomplicated patients

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Siham Accacha, MD
NYU Langone Hospital
Mineola, NY

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. 

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Siham Accacha, MD - Arbor Pharmaceutical, speaker bureau and Ascendis: Advisory Board

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.  

The following SPC members reported no relevant financial relationships: 

Michelle Cordoba Kissee, MD - No conflicts
Isha Mittal, MPH - No conflicts
Ashton Santo - No conflicts

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.